Clinical trial
A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors
NCT00437736 · Valerio Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00437736 |
|---|---|
| Title | A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors |
| Official title | Phase I Dose Finding and Pharmacokinetic Study of Intravenous APO010, a Recombinant Form of Human Fas Ligand, in Patients With Solid Tumors |
| Acronym | AP1001 |
| Lead sponsor | Valerio Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | APO010 |
| Enrollment | 26 |
| Start date | Feb 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Feb 21, 2007 |
| Last update posted | Sep 17, 2015 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: